Screener
Denali Therapeutics Inc. DNLI Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from exercise of awards under equity incentive plans | 21,700 | 4,652 |
| Payments for finance lease right-of-use asset | (38) | (6,791) |
| Net cash provided by (used in) financing activities | 234,028 | (2,139) |
| Net decrease in cash, cash equivalents and restricted cash | (3,796) | (32,222) |
| Cash, cash equivalents and restricted cash at beginning of period | 208,432 | 176,535 |
| Cash, cash equivalents and restricted cash at end of period | $204,636 | $144,313 |
| Supplemental disclosures of cash flow information | ||
| Payment due on intangible asset acquired | $7,200 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s net change in cash?
- Denali Therapeutics Inc. (DNLI) reported net change in cash of -$186.1M in Q2 2026.
- How has Denali Therapeutics Inc.'s net change in cash changed year-over-year?
- Denali Therapeutics Inc.'s net change in cash decreased by 320.9% year-over-year, from $84.26M to -$186.1M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Denali Therapeutics Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude